Gilead Sciencesvs.Moderna
GILD vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 6.7× larger than Moderna by market cap; year to date, Moderna leads (+371.0% vs +19.6%).
Side by side
| GILD | MRNA | |
|---|---|---|
| Market cap | $170B | $25.2B |
| Price | $148.77 | $158.83 |
| Today | +1.4% | +14.4% |
| Return YTD | +19.6% | +371.0% |
| Return 1Y | +27.9% | +412.1% |
| P/E | — | — |
| P/S | 5.6 | 11.3 |
| P/B | 14.4 | 3.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More GILD & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.
See where GILD and MRNA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →